Guidance
1 Guidance
1 Guidance
1.1 Current evidence on the safety and efficacy of high dose rate (HDR) brachytherapy in combination with external-beam radiotherapy for localised prostate cancer appears adequate to support the use of this procedure provided that the normal arrangements are in place for consent, audit and clinical governance.
1.2 A multidisciplinary team should be involved in the planning and use of this procedure.